|
[´ã´ç¾÷¹«] ¤Ó ´ã´ç ¾÷¹«
´Ù¾çÇÑ modality (antibody-drug conjugate, peptide-drug conjugate, degrader-antibody conjugate, nanoparticles µî) ¸¦ ÀÌ¿ëÇÏ¿© ½Å¾à°³¹ßÀ» ÇÏ´Â New Modality Center¸¦ ¸®µå.
New modality¸¦ ÀÌ¿ëÇÑ ½Å¾à°³¹ßÀ» À§ÇÑ open innovation À» ´ã´ç.
New modality¸¦ ´Ù¾çÇÑ Áúº´±º (oncology, neuroscience, inflammation µî)¿¡¼ Å×½ºÆ®ÇÒ ¼ö ÀÖ´Â ¿¬±¸¹æ¹ý ¹× ½ÇÇè system ±¸ÃàÀ» Áöµµ.
½Å¾à¿¬±¸¼Ò¿Í LCB R&D Àü¹ÝÀ» Áö¿øÇÒ ¼ö ÀÖ´Â functional groupÀÇ ±¸ÃàÀ» ¸®µå.
¤Ó ¸ðÁýºÎ¹® ¹× »ó¼¼³»¿ë [ Áö¿ø ÀÚ°Ý ]
Àü°ø : »ýÈÇÐ, ºÐÀÚ »ý¹°ÇÐ, ¼¼Æ÷ »ý¹°ÇÐ, ¸é¿ªÇÐ, ½Å°æ°úÇÐ ¶Ç´Â °ü·Ã °úÇÐ ºÐ¾ß
Çз : ¹Ú»ç ÀÌ»ó
°æ·Â»çÇ× : ÃÖ¼Ò 8³â ÀÌ»ó Industry °æÇè / ÃÖ¼Ò 5³â ÀÌ»ó ÆÀ ¸®µå °æÇè.
[ Çʼö ¾÷¹«°æÇè µî ±âŸ»çÇ× ]
»ç³» ¹× »ç¿Ü °øµ¿¿¬±¸¸¦ À§ÇØ ÇʼöÀûÀÎ ¿øÈ°ÇÑ communication skill.
ÇØ¿Ü°øµ¿¿¬±¸¸¦ À§ÇÑ ¿øÈ°ÇÑ ¿µ¾î ±¸»ç´É·Â.
[ ¿ì´ë »çÇ× ]
Antibody-drug conjugate, peptide-drug conjugate ȤÀº nanoparticleÀ» ÀÌ¿ëÇÑ ½Å¾à°³¹ßÀ» ÀÌ¿ëÇØ IND filingÀ» ÇØº» °æÇèÀÚ
|
[ÀÚ°Ý¿ä°Ç] °æ·Â: °æ·Â 8³â¡è ÇзÂ: ¹Ú»çÁ¹¾÷ Á÷¹«±â¼ú: ´º¸ð´Þ¸®Æ¼
|